In ambulatory patients with solid cancer, routine thromboprophylaxis to prevent venous thromboembolism is not recommended. Several risk prediction scores to identify cancer patients at high risk of venous thromboembolism have been proposed, but their clinical usefulness remains a matter of debate. We evaluated and directly compared the performance of the Khorana, Vienna, PROTECHT, and CONKO scores in a multinational, prospective cohort study. Patients with advanced cancer were eligible if they were planned for chemotherapy or had started chemotherapy in the previous 3 months. The primary outcome was objectively confirmed symptomatic or incidental deep vein thrombosis or pulmonary embolism during a 6-month follow-up period. A total of 876 patients were enrolled, of whom 260 (30%) had not yet received chemotherapy. Fifty-three patients (6.1%) developed venous thromboembolism. The c-statistics of the scores ranged from 0.50 to 0.57. At the conventional positivity threshold of 3 points, the scores classified 13% to 34% of patients as high risk; the 6-month venous thromboembolism incidence in these patients ranged from 6.5% (95% CI, 2.8-12) for the Khorana score to 9.6% (95% CI, 6.6-13) for the PROTECHT score. High risk patients had a significantly increased risk of venous thromboembolism when using the Vienna (subhazard ratio 1.7; 95% CI 1.0-3.1) or PROTECHT scores (subhazard ratio 2.1; 95% CI 1.2-3.6). In conclusion, the prediction scores performed poorly in predicting venous thromboembolism in cancer patients. The Vienna CATS and PROTECHT scores appear to discriminate better between low and high risk patients, but further improvements are needed prior to considering introduction in clinical practice.

Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study

DI NISIO, Marcello;PORRECA, Ettore;DE TURSI, Michele;
2017-01-01

Abstract

In ambulatory patients with solid cancer, routine thromboprophylaxis to prevent venous thromboembolism is not recommended. Several risk prediction scores to identify cancer patients at high risk of venous thromboembolism have been proposed, but their clinical usefulness remains a matter of debate. We evaluated and directly compared the performance of the Khorana, Vienna, PROTECHT, and CONKO scores in a multinational, prospective cohort study. Patients with advanced cancer were eligible if they were planned for chemotherapy or had started chemotherapy in the previous 3 months. The primary outcome was objectively confirmed symptomatic or incidental deep vein thrombosis or pulmonary embolism during a 6-month follow-up period. A total of 876 patients were enrolled, of whom 260 (30%) had not yet received chemotherapy. Fifty-three patients (6.1%) developed venous thromboembolism. The c-statistics of the scores ranged from 0.50 to 0.57. At the conventional positivity threshold of 3 points, the scores classified 13% to 34% of patients as high risk; the 6-month venous thromboembolism incidence in these patients ranged from 6.5% (95% CI, 2.8-12) for the Khorana score to 9.6% (95% CI, 6.6-13) for the PROTECHT score. High risk patients had a significantly increased risk of venous thromboembolism when using the Vienna (subhazard ratio 1.7; 95% CI 1.0-3.1) or PROTECHT scores (subhazard ratio 2.1; 95% CI 1.2-3.6). In conclusion, the prediction scores performed poorly in predicting venous thromboembolism in cancer patients. The Vienna CATS and PROTECHT scores appear to discriminate better between low and high risk patients, but further improvements are needed prior to considering introduction in clinical practice.
File in questo prodotto:
File Dimensione Formato  
045 Van Es COMPARISON RISK Haemato 2017.pdf

accesso aperto

Tipologia: PDF editoriale
Dimensione 309.92 kB
Formato Adobe PDF
309.92 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11564/668533
Citazioni
  • ???jsp.display-item.citation.pmc??? 85
  • Scopus 179
  • ???jsp.display-item.citation.isi??? 161
social impact